Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Background: Rotavirus infection is a common cause of acute gastroenteritis among uner-5-years-old children, especially in those countries which has not implemented a rotavirus vaccination program. The aim of this study was to estimate the safety and efficacy of Rotarix® and Rotateq® vaccines. Methods: We performed a systematic literature review in randomized controlled trials and quasiexperimental studies on children of general population. We searched Medline, Ovid, ISI, Cochrane, Proquest, Scopus, DARE, HTA and NHSEED databases. Meta-analysis was performed and we assessed heterogeneity using Q test and used random model for pooling estimate of efficacy of rotavirus vaccines (Rotarix® and Rotateq®). Publication bias was assessed via Egger’s and Begg’s tests. Findings: Twelve eligible studies were included in meta-analysis. The pooled estimate of vaccine efficacy for Rotarix® and Rotateq® was 80% (95% CI: 0.68-0.87) and 70% (95% CI: 0.65-0.85), respectively. Relative risk of side effects in vaccinated versus no-vaccinated groups was in the range of 0.83 to 1.2. Conclusion: The results show that vaccination against rotavirus prevented sever and none-severe diarrhea in children and could reduce burden of the disease. It is necessary to perform costeffectiveness studies for implementing rotavirus vaccination in Iran.



Journal of Isfahan Medical School

Publication Date





1605 - 1622